Oxford Cancer Biomarkers closes funding round led by Plutus Investment Group LLP

OXFORD, UK – 3rd April 2023 – Oxford Cancer Biomarkers Ltd (OCB), a leader in AI-driven, precision cancer diagnostics, has successfully closed its latest investment round.

Plutus Investment Group LLP led the round, with participation from new and existing investors including UK-based VC funds Esperante Ventures, Longwall Ventures and Panacea Innovation, alongside entrepreneur and professional investor, Mr BK Lee.

Funds will be used to drive UK commercialisation of OncoProg® and ToxNav®, position the products for launch in major global markets through strategic partnerships and advance the development of pipeline products in digital pathology and pharmacogenomics.

Plutus Investments Group LLP is a multi-family office backing entrepreneurs in Europe and the USA, focused on Life Sciences, Biotech, Fintech and Tech investments. Mohammed Jamal, CEO of Plutus said “We are very excited to be part of the OCB adventure, and very proud to be working with such a skilled team and be leaders in Precision Medicine”.